Novartis presents seven-year disability outcomes for MS drug Kesimpta at neurology conference.

Novartis will present new data on its drug Kesimpta for people with relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2025 Annual Meeting in San Diego. The presentation includes seven-year disability outcomes and safety analysis from continuous treatment with Kesimpta. The company will also share data on other potential treatments for neurological conditions, including remibrutinib and iptacopan.